

P H A R M A C Y

Feeling well. Living better.

Dermatology Referral Form

Publix Specialty Pharmacy (#3212)

7616 Southland Blvd, Suite 112
Orlando, FL 32809
Phone: 855-797-8254
Fax: 863-413-5723

Patient Information [Attach copy of front and back of prescription insurance card(s)]

Patient's First Name: _____ Patient's Last Name: _____ Date of Birth: ___/___/___ Male Female
Address: _____ City: _____ State: _____ Zip: _____
Primary Phone Number: (____) _____ Alt. Phone Number: (____) _____ Caregiver name: _____

Clinical Information [Attach copy of labs and office notes]

Diagnosis code(s): _____ Diagnosis: Psoriasis (PsO) Psoriatic Arthritis (PsA) Hidradenitis Suppurativa (HS) Atopic dermatitis Other: _____
Treatment status: New to therapy, previously denied by insurance: No Yes, include copy of denial letter Enroll in copay card/ bridge program if available and eligible: No Yes
 Continuation of therapy, start date: ___/___/___ Is the patient on samples? No Yes Weight: _____ kg lb, Height: _____ cm in
TB test results (within 6 months): N/A Negative Positive, Date of TB test: ___/___/___ Allergies: NKDA Other: _____
Prior therapy, reason for discontinuation, and treatment dates: _____

MEDICATION	DOSE/STRENGTH	DIRECTIONS	DISPENSE QTY FOR	REFILLS
<input type="checkbox"/> Cosentyx (secukinumab)	<input type="checkbox"/> 150 mg/mL Sensoready pen <input type="checkbox"/> 150 mg/mL PFS	<input type="checkbox"/> Initial Dose: Inject 300 mg (2 x 150 mg) SC once a week for 5 weeks (on days 1, 8, 15, 22, and 29) Maintenance Dose: <input type="checkbox"/> Inject 300 mg (2 x 150 mg) SC every 4 weeks <input type="checkbox"/> Inject 150 mg SC every 4 weeks	56 days <input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	0 _____
<input type="checkbox"/> Dupixent (dupilumab)	300 mg/2 mL PFS	<input type="checkbox"/> Initial Dose: Inject 600 mg (2 x 300 mg) SC on day 1, then 300 mg every 2 weeks starting on day 15 <input type="checkbox"/> Maintenance Dose: Inject 300 mg SC every 2 weeks	42 days <input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	0 _____
<input type="checkbox"/> Enbrel (etanercept)	<input type="checkbox"/> 50 mg/mL SureClick pen <input type="checkbox"/> 50 mg/mL PFS <input type="checkbox"/> 25 mg/0.5 mL PFS	<input type="checkbox"/> Initial Dose: Inject 50 mg SC twice a week (72–96 hours apart) <input type="checkbox"/> Maintenance Dose: Inject 50 mg SC once a week	84 days <input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	0 _____
<input type="checkbox"/> Humira (adalimumab)	<input type="checkbox"/> PsO Starter Kit: 4 x 40 mg pen <input type="checkbox"/> 40 mg PFS	Initial Dose (for PsO): Inject 80 mg (2 x 40 mg) SC on day 1, then 40 mg every 2 weeks starting on day 8	35 days	0
	<input type="checkbox"/> HS Starter Kit: 6 x 40 mg pen <input type="checkbox"/> 40 mg PFS	Initial Dose (for HS): <input type="checkbox"/> Inject 160 mg (4 x 40 mg) SC on day 1, then 80 mg (2 x 40 mg) on day 15 <input type="checkbox"/> Inject 80 mg (2 x 40 mg) SC on days 1, 2, and 15	28 days	0
	<input type="checkbox"/> 40 mg pen <input type="checkbox"/> 40 mg PFS	Maintenance Dose: <input type="checkbox"/> Inject 40 mg SC every 2 weeks <input type="checkbox"/> Inject 40 mg SC once a week	<input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	_____
<input type="checkbox"/> Otezla (apremilast)	<input type="checkbox"/> Starter Pack: 55 tablets	Initial dose: Take as directed per package instructions	28 days	0
	<input type="checkbox"/> 30mg tablet	Maintenance dose: <input type="checkbox"/> Take 1 tab PO BID <input type="checkbox"/> Take 1 tab PO once a day (for severe renal impairment)	<input type="checkbox"/> 30 days <input type="checkbox"/> 90 days	_____
<input type="checkbox"/> Remicade (infliximab) <input type="checkbox"/> Inflectra (infliximab-dyyb) <input type="checkbox"/> Renflexis (infliximab-abda) Patient weight: _____	100 mg vial	Initial Dose: <input type="checkbox"/> Infuse _____ mg (_____ mg/kg) IV over at least 2 hours on days 1, 15, and 43	3 doses	0
		Maintenance Dose: <input type="checkbox"/> Infuse _____ mg (_____ mg/kg) IV over at least 2 hours every 8 weeks	56 days	_____
Include: <input type="checkbox"/> Sterile water for inj <input type="checkbox"/> Sodium chloride 0.9% inj	10 mL vial 250 mL bag	Use 10mL to reconstitute each 100 mg infliximab vial before dilution Dilute reconstituted infliximab to a final concentration of 0.4 to 4 mg/mL	QS	_____
<input type="checkbox"/> Siliq (brodalumab)	210 mg/1.5 mL PFS	<input type="checkbox"/> Initial Dose: Inject 210 mg SC on days 1 and 8, then every 2 weeks starting on day 15	42 days	0
		<input type="checkbox"/> Maintenance Dose: Inject 210 mg SC every 2 weeks	<input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	_____
<input type="checkbox"/> Stelara (ustekinumab) Patient weight: _____	<input type="checkbox"/> 45 mg/0.5 mL PFS <input type="checkbox"/> 90 mg/ mL PFS	<input type="checkbox"/> Initial Dose: Inject SC on day 1, then 4 weeks later on day 29	2 doses	0
		<input type="checkbox"/> Maintenance Dose: Inject SC every 12 weeks	84 days	_____
<input type="checkbox"/> Tremfya (guselkumab)	100 mg/mL PFS	<input type="checkbox"/> Initial Dose: Inject 100mg SC on day 1, then 4 weeks later on day 29	2 doses	0
		<input type="checkbox"/> Maintenance Dose: Inject 100mg SC every 8 weeks	56 days	_____

Prescriber Information [Ship to prescriber: Never Always First fill only, appointment date: ___/___/___] Use Cover My Meds: No Yes

Name: _____ DEA# _____ NPI # _____
Address: _____ City: _____ State: _____ Zip: _____
Office Phone Number: (____) _____ Fax Number: (____) _____ Office Contact: _____

I authorize Publix Pharmacy representatives to act on behalf of the prescriber to initiate and complete the insurance prior authorization process

Prescriber's signature: _____
(stamps not accepted) Substitution allowed _____ Date Dispense as written/ Do not substitute _____ Date

For states requiring hand written expressions to prevent substitution, write here:

This document, and any attachments, are intended solely for the use of the individual(s) to whom they are addressed. They may contain confidential information and/or protected health information (PHI) that is protected by law. If you believe you were not the intended recipient of this document, you are hereby notified that any review, dissemination, distribution, printing or copying of this document and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and destroy this document and any attachments. If you properly received this document, you should maintain its contents in confidence in accordance with applicable law.